Compare VAC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAC | MESO |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2011 | N/A |
| Metric | VAC | MESO |
|---|---|---|
| Price | $68.85 | $14.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $68.56 | N/A |
| AVG Volume (30 Days) | ★ 637.5K | 229.6K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,032,000,000.00 | N/A |
| Revenue This Year | $54.41 | $633.98 |
| Revenue Next Year | $2.06 | $29.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $44.58 | $9.61 |
| 52 Week High | $86.33 | $21.50 |
| Indicator | VAC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 68.33 | 32.47 |
| Support Level | $63.42 | $14.53 |
| Resistance Level | $74.88 | $16.32 |
| Average True Range (ATR) | 3.36 | 0.52 |
| MACD | 1.47 | -0.23 |
| Stochastic Oscillator | 78.35 | 27.85 |
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.